CL2014002935A1 - Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador - Google Patents

Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador

Info

Publication number
CL2014002935A1
CL2014002935A1 CL2014002935A CL2014002935A CL2014002935A1 CL 2014002935 A1 CL2014002935 A1 CL 2014002935A1 CL 2014002935 A CL2014002935 A CL 2014002935A CL 2014002935 A CL2014002935 A CL 2014002935A CL 2014002935 A1 CL2014002935 A1 CL 2014002935A1
Authority
CL
Chile
Prior art keywords
laquinimod
treat
carrier
dosage form
multiple sclerosis
Prior art date
Application number
CL2014002935A
Other languages
English (en)
Spanish (es)
Inventor
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2014002935A1 publication Critical patent/CL2014002935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014002935A 2012-05-02 2014-10-29 Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador CL2014002935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02

Publications (1)

Publication Number Publication Date
CL2014002935A1 true CL2014002935A1 (es) 2015-03-06

Family

ID=49514859

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002935A CL2014002935A1 (es) 2012-05-02 2014-10-29 Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador

Country Status (21)

Country Link
US (3) US20130303569A1 (cg-RX-API-DMAC7.html)
EP (1) EP2844255A4 (cg-RX-API-DMAC7.html)
JP (2) JP2015515985A (cg-RX-API-DMAC7.html)
KR (1) KR20150013658A (cg-RX-API-DMAC7.html)
CN (2) CN105832733A (cg-RX-API-DMAC7.html)
AR (1) AR090885A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013256352A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014027010A2 (cg-RX-API-DMAC7.html)
CA (1) CA2870684A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014002935A1 (cg-RX-API-DMAC7.html)
EA (1) EA201492010A1 (cg-RX-API-DMAC7.html)
HK (1) HK1206246A1 (cg-RX-API-DMAC7.html)
IL (1) IL235337A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014013039A (cg-RX-API-DMAC7.html)
PE (1) PE20150161A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502447A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201406594UA (cg-RX-API-DMAC7.html)
TW (2) TW201347762A (cg-RX-API-DMAC7.html)
UY (1) UY34775A (cg-RX-API-DMAC7.html)
WO (1) WO2013166166A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408820B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
TW201345527A (zh) 2012-02-03 2013-11-16 Teva Pharma 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AU2013329348A1 (en) * 2012-10-12 2015-05-28 Teva Pharmaceutical Industries Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症
EA201591699A1 (ru) 2013-03-14 2016-02-29 Тева Фармасьютикал Индастриз Лтд. Кристаллы лаквинимода натрия и улучшенный способ их производства
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
US20150306088A1 (en) * 2014-04-29 2015-10-29 Teva Pharmaceutical Industries, Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
WO2020016850A1 (en) * 2018-07-20 2020-01-23 Merck Patent Gmbh A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症

Also Published As

Publication number Publication date
US20160000775A1 (en) 2016-01-07
PH12014502447A1 (en) 2015-01-12
PE20150161A1 (es) 2015-02-22
AR090885A1 (es) 2014-12-10
UY34775A (es) 2013-11-29
CN104284663A (zh) 2015-01-14
CN105832733A (zh) 2016-08-10
US20130303569A1 (en) 2013-11-14
WO2013166166A1 (en) 2013-11-07
TW201804997A (zh) 2018-02-16
US20150265592A1 (en) 2015-09-24
IL235337A0 (en) 2014-12-31
TW201347762A (zh) 2013-12-01
MX2014013039A (es) 2015-02-04
KR20150013658A (ko) 2015-02-05
JP2015515985A (ja) 2015-06-04
CA2870684A1 (en) 2013-11-07
JP2017222691A (ja) 2017-12-21
EA201492010A1 (ru) 2015-06-30
EP2844255A4 (en) 2015-10-14
BR112014027010A2 (pt) 2017-06-27
SG11201406594UA (en) 2014-11-27
EP2844255A1 (en) 2015-03-11
ZA201408820B (en) 2016-06-29
HK1206246A1 (en) 2016-01-08
AU2013256352A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
PH12014500386A1 (en) Combination treatment for hepatitis c
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
PH12015500823A1 (en) Modified release formulations for oprozomib
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
IL234093A0 (en) Preparations and dosages for oral administration and their uses for the treatment of Gaucher's disease
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
IN2014DN09240A (cg-RX-API-DMAC7.html)
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.
EP3065737A4 (en) Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form
EA201200799A1 (ru) Гепатопротекторное средство
UA85800U (ru) Способ интенсивной терапии рецидива простой шизофрении с непрерывным течением и агрессивным поведением
RU2012135942A (ru) Способ лечения больных желчекаменной болезнью первой стадии
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
UA77604U (ru) Производное 1,2,4-триазола, проявляющее актопротекторную активность